Expression of peripheral benzodiazepine receptor (PBR) in human tumors: Relationship to breast, colorectal, and prostate tumor progression
Expression of peripheral benzodiazepine receptor (PBR) in human tumors: Relationship to breast, colorectal, and prostate tumor progression
复制标题
DOI：
10.1081/rrs-120025210
复制
发表时间：
2003-01-01
影响因子：
2.8
通讯作者：
Papadopoulos, V
中科院分区：
文献类型：
--
作者：
Han, ZQ;Slack, RS;Papadopoulos, V
高水平的外周型苯二氮卓受体（PBR）是地西泮的替代结合位点，是体外侵袭性人类乳腺癌细胞表型的一部分。我们通过免疫组织化学检查了多种癌症类型的正常组织和肿瘤中的 PBR 水平和分布。在正常乳腺组织、纤维腺瘤、原发性和转移性腺癌中，PBR 水平与肿瘤的侵袭和转移能力平行地逐渐增加（p < 0.0001）。在结直肠癌和前列腺癌中，肿瘤中的 PBR 水平也高于相应的非肿瘤、组织和良性病变 (p < 0.0001)。相反，PBR 高度集中在正常肾上腺皮质细胞和肝细胞中，而在肾上腺皮质肿瘤和肝癌中，PBR 水平降低。此外，与正常皮肤相比，恶性皮肤肿瘤的 PBR 表达降低。这些结果表明，PBR表达升高并不是侵袭性肿瘤的常见特征，而是可能仅限于某些癌症，例如乳腺癌、结肠直肠癌和前列腺组织的癌症，其中PBR表达升高与肿瘤进展相关。因此，我们认为 PBR 过度表达可以作为乳腺癌、结直肠癌和前列腺癌侵袭性表型的新预后指标。
High levels of peripheral-type benzodiazepine receptor (PBR), the alternative-binding site for diazepam, are part of the aggressive human breast cancer cell phenotype in vitro. We examined PBR levels and distribution in normal tissue and tumors from multiple cancer types by immunohistochemistry. Among normal breast tissues, fibroadenomas, primary and metastatic adenocarcinomas, there is a progressive increase in PBR levels parallel to the invasive and metastatic ability of the tumor (p < 0.0001). In colorectal and prostate carcinomas, PBR levels were: also higher in tumor than in the corresponding non-tumoral, tissues and benign lesions (p < 0.0001).,In contrast, PBR was highly concentrated in normal adrenal cortical cells and hepatocytes, whereas in adrenocortical tumors and hepatomas PBR levels were decreased. Moreover, malignant skin tumors showed decreased PBR expression compared with normal skin. These results indicate that elevated PBR expression is not a common feature of aggressive tumors, but rather may be limited to certain cancers, such as those of breast, colon-rectum and prostate tissues, where elevated PBR expression is associated with tumor progression. Thus, we propose that PBR overexpression could serve as a novel prognostic indicator of an aggressive phenotype in breast, colorectal and prostate cancers.